To evaluate the therapeutic efficacy of AAV-GLA gene therapy in a symptomatic model, we used G3STg/+Gla−/y mice, which closely mimic classical Fabry disease through elevated serum Gb3, organ accumulation, and progressive renal impairment. This evidence concerns the gene GLA and Fabry disease.